146 related articles for article (PubMed ID: 38408903)
1. The impact of Karnofsky performance status on prognosis of patients with hepatocellular carcinoma in liver transplantation.
Zhou J; Ye D; Zhang S; Ding J; Zhang T; Chen Z; Xu F; Ren S; Hu Z
BMC Gastroenterol; 2024 Feb; 24(1):85. PubMed ID: 38408903
[TBL] [Abstract][Full Text] [Related]
2. Karnofsky performance status before and after liver transplantation predicts graft and patient survival.
Thuluvath PJ; Thuluvath AJ; Savva Y
J Hepatol; 2018 Oct; 69(4):818-825. PubMed ID: 29883596
[TBL] [Abstract][Full Text] [Related]
3. Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions.
Schmitt TM; Kumer SC; Shah N; Argo CK; Northup PG
Ann Hepatol; 2010; 9(4):390-6. PubMed ID: 21057157
[TBL] [Abstract][Full Text] [Related]
4. Intent-to-treat analysis of liver transplant for hepatocellular carcinoma in the MELD era: impact of hepatitis C and advanced status.
Hu Z; Li Z; Xiang J; Zhou J; Yan S; Wu J; Zhou L; Zheng S
Dig Dis Sci; 2014 Dec; 59(12):3062-72. PubMed ID: 25008426
[TBL] [Abstract][Full Text] [Related]
5. Karnofsky performance status predicts outcomes in candidates for simultaneous liver-kidney transplant.
Shamseddeen H; Pike F; Ghabril M; Patidar KR; Desai AP; Nephew L; Anderson M; Kubal C; Chalasani N; Orman ES
Clin Transplant; 2021 Feb; 35(2):e14190. PubMed ID: 33320383
[TBL] [Abstract][Full Text] [Related]
6. Impact of donor age on liver transplant outcomes in patients with hepatocellular carcinoma: analysis of the SRTR database.
Zhou J; Huang Z; Chen Z; Xu F; Tong R; Zheng S
BMC Gastroenterol; 2021 Apr; 21(1):195. PubMed ID: 33931011
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance.
Gutin L; Yao F; Dodge JL; Grab J; Mehta N
JAMA Netw Open; 2019 Aug; 2(8):e1910326. PubMed ID: 31469395
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
[TBL] [Abstract][Full Text] [Related]
9. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA
Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694
[TBL] [Abstract][Full Text] [Related]
10. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
11. Patients with Alcoholic Liver Disease Have Worse Functional Status at Time of Liver Transplant Registration and Greater Waitlist and Post-transplant Mortality Which Is Compounded by Older Age.
McCabe P; Galoosian A; Wong RJ
Dig Dis Sci; 2020 May; 65(5):1501-1511. PubMed ID: 31642005
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study.
Gorgen A; Galvin Z; Huang AC; Vinaixa C; O'Rourke JM; Francoz C; Hansen BE; Durand F; Elsharkawy AM; Shah T; Berenguer M; Rubin A; Calatayud D; Mehta N; Terrault NA; Lilly LB; Selzner N; Sapisochin G
Transplantation; 2020 Oct; 104(10):2087-2096. PubMed ID: 31978002
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Wait-List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates.
Ziogas IA; Hickman LA; Matsuoka LK; Izzy M; Montenovo MI; Rega SA; Feurer ID; Alexopoulos SP
Liver Transpl; 2020 Sep; 26(9):1112-1120. PubMed ID: 32475062
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics Associated With Posttransplant Survival Among Adults 70 Years Old or Older Undergoing Liver Transplantation.
Wang M; Ge J; Ha N; Shui AM; Huang CY; Cullaro G; Lai JC
J Clin Gastroenterol; 2024 May-Jun 01; 58(5):516-521. PubMed ID: 37279205
[TBL] [Abstract][Full Text] [Related]
15. Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score.
Goldberg D; Mantero A; Newcomb C; Delgado C; Forde KA; Kaplan DE; John B; Nuchovich N; Dominguez B; Emanuel E; Reese PP
J Hepatol; 2021 Jun; 74(6):1398-1406. PubMed ID: 33453328
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant.
Lai Q; Sapisochin G; Gorgen A; Vitale A; Halazun KJ; Iesari S; Schaefer B; Bhangui P; Mennini G; Wong TCL; Uemoto S; Lin CC; Mittler J; Ikegami T; Yang Z; Frigo AC; Zheng SS; Soejima Y; Hoppe-Lotichius M; Chen CL; Kaido T; Lo CM; Rossi M; Soin AS; Finkenstedt A; Emond JC; Cillo U; Lerut JP
JAMA Surg; 2021 Sep; 156(9):e213112. PubMed ID: 34259797
[TBL] [Abstract][Full Text] [Related]
18. Living or Brain-dead Donor Liver Transplantation for Hepatocellular Carcinoma: A Multicenter, Western, Intent-to-treat Cohort Study.
Azoulay D; Audureau E; Bhangui P; Belghiti J; Boillot O; Andreani P; Castaing D; Cherqui D; Irtan S; Calmus Y; Chazouillères O; Soubrane O; Luciani A; Feray C
Ann Surg; 2017 Dec; 266(6):1035-1044. PubMed ID: 27617853
[TBL] [Abstract][Full Text] [Related]
19. Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation.
Orci LA; Berney T; Majno PE; Lacotte S; Oldani G; Morel P; Mentha G; Toso C
Br J Surg; 2015 Sep; 102(10):1250-7. PubMed ID: 26098966
[TBL] [Abstract][Full Text] [Related]
20. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation.
Goldaracena N; Gorgen A; Doyle A; Hansen BE; Tomiyama K; Zhang W; Ghanekar A; Lilly L; Cattral M; Galvin Z; Selzner M; Bhat M; Selzner N; McGilvray I; Greig PD; Grant DR; Sapisochin G
J Hepatol; 2019 Apr; 70(4):666-673. PubMed ID: 30630009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
